Biosimilars Drive Cost Savings and Provider Confidence in Healthcare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CAH?
Source: PRnewswire
- Significant Cost Savings: Since 2015, biosimilars have generated over $56 billion in savings for the U.S. healthcare system, not only reducing treatment costs but also enhancing access to care and increasing the overall value of the healthcare system.
- Enhanced Clinical Confidence: A survey of 101 physician practices revealed that nearly 99% of providers feel comfortable explaining biosimilars to patients, demonstrating strong clinical confidence that supports the adoption of these therapies in clinical settings.
- Oncology Market Share Growth: Biosimilars in oncology achieve an average market share of 81% within five years of launch, indicating their critical role and potential in cancer treatment, with expectations for more new approvals in the near future.
- Stable Reimbursement Mechanisms: With 68% of practices rating consistent reimbursement as
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to fall
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 229.230
Low
209.00
Averages
225.18
High
244.00
Current: 229.230
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Recap: Oil Prices Surge, CrowdStrike Upgraded
- Market Volatility: The S&P 500 fell on Monday but briefly rebounded after the U.S. and Israel launched an attack on Iran, causing oil prices to spike; WTI crude prices, while off their highs, indicate a defensive market stance.
- CrowdStrike Upgrade: Piper Sandler upgraded CrowdStrike from hold to buy with a $520 price target, arguing that the nearly 19% year-to-date pullback is excessive, and sees AI as an opportunity rather than a threat, boosting market confidence.
- Nvidia Strategic Investments: Nvidia shares rose over 3% after being named a top pick by Morgan Stanley, with analysts noting that despite stagnant stock performance in the last two quarters, business has strengthened; the company announced $2 billion investments in both Coherent and Lumentum, highlighting its strategic focus in optics technology.
- Investor Recommendations: Jim Cramer advised investors without Nvidia positions to buy the stock, asserting that its current depressed price won't last long, even as Monday's gains still left shares lower year-to-date.
See More
Jim Cramer's Investment Advice Amid Middle East Tensions
- Selective Investment Strategy: Jim Cramer advises investors to be selective following the U.S.-Israeli conflict with Iran, noting that while stocks initially sold off, there is no need for a full portfolio overhaul, particularly as the long-term narrative around artificial intelligence remains intact.
- Healthcare Sector Opportunities: Cramer recommends investing in the healthcare sector, asserting it will remain insulated from economic fallout, and initiated a position in Cardinal Health on Monday morning, which plays a crucial role in healthcare distribution and is pursuing growth through acquisitions.
- Reducing Oil Exposure: Cramer highlights that the market reaction creates opportunities to lighten oil positions, suggesting a 50% reduction in holdings due to inflated valuations from rising oil prices, drawing on historical patterns where such stocks tend to decline after initial spikes.
- Cautious on Consumer Staples: While Procter & Gamble is typically viewed as a classic defensive stock, Cramer expresses caution, indicating that rising oil prices could squeeze consumer spending, potentially impacting the performance of such stocks.
See More
Investment Analysis of Cardinal Health
- New Investment Move: Shortly after the opening bell, Jim Cramer's Charitable Trust will purchase 170 shares of Cardinal Health at approximately $229, resulting in a 1% ownership stake, reflecting confidence in the company's prospects.
- Market Reaction: Stocks are expected to open sharply lower on Monday due to weekend strikes in Iran, with crude oil prices climbing above $70, heightening concerns about geopolitical risks and inflation, which complicates the market landscape.
- Long-Term Growth Potential: Cardinal Health plays a crucial role in the U.S. healthcare sector, generating 99% of its revenue domestically, and the ongoing increase in the aging population in the U.S. is expected to provide significant long-term growth tailwinds over the next three decades.
- Profitability Enhancement: Despite market volatility, Cardinal Health's stock has risen over 70% in the past 12 months and approximately 10% year-to-date, trading at a price-to-earnings ratio of 21 times, indicating strong potential for sustained double-digit earnings growth.
See More
Cardinal Health Added to Watchlist
- Strong Industry Position: Cardinal Health serves as a backbone of the U.S. healthcare industry, supplying and distributing medicines and medical products to hospitals, retail pharmacies, and clinics, thereby ensuring its core role in the healthcare supply chain.
- Demographic Tailwind: With the continuous increase in the U.S. population aged 65 and over, Cardinal Health is expected to benefit from this long-term trend, as over 50% of this age group takes four or more medications, driving business growth.
- Market Reaction: Although shares sold off sharply on February 12 due to a logistics company announcing a new tool, the market quickly recognized the overreaction, and the stock rebounded swiftly, demonstrating its economic resilience.
- Attractive Valuation: Despite Cardinal Health's stock gaining about 10% over the past 12 months, it trades at just 21 times 2026 earnings estimates, which remains attractive relative to its historical levels, reflecting its potential for sustained double-digit earnings per share growth.
See More
Biosimilars Drive Cost Savings and Provider Confidence in Healthcare
- Significant Cost Savings: Since 2015, biosimilars have generated over $56 billion in savings for the U.S. healthcare system, not only reducing treatment costs but also enhancing access to care and increasing the overall value of the healthcare system.
- Enhanced Clinical Confidence: A survey of 101 physician practices revealed that nearly 99% of providers feel comfortable explaining biosimilars to patients, demonstrating strong clinical confidence that supports the adoption of these therapies in clinical settings.
- Oncology Market Share Growth: Biosimilars in oncology achieve an average market share of 81% within five years of launch, indicating their critical role and potential in cancer treatment, with expectations for more new approvals in the near future.
- Stable Reimbursement Mechanisms: With 68% of practices rating consistent reimbursement as
See More
Beck Bode Acquires New Stake in Churchill Downs
- New Investment Position: On February 6, 2026, Beck Bode, LLC established a new position in Churchill Downs by acquiring 154,871 shares valued at $17.62 million, indicating confidence in the company's future growth potential.
- Asset Allocation Significance: This acquisition represents 2.93% of Beck Bode's $601.19 million in reportable U.S. equity assets, highlighting the importance of Churchill Downs within its diversified investment portfolio.
- Market Performance Insight: As of February 6, 2026, Churchill Downs shares were priced at $93.55, reflecting a 23.8% decline over the past year, significantly underperforming the S&P 500 by 37.76 percentage points, raising concerns about its future profitability.
- Revenue Diversification Strategy: Churchill Downs leverages its iconic racing assets and technology across live racing, online wagering, and casino operations, aiming for long-term cash flow growth despite potential short-term earnings pressure from aggressive investments in new properties and gaming capacity.
See More
Market Recap: Oil Prices Surge, CrowdStrike Upgraded
- Market Volatility: The S&P 500 fell on Monday but briefly rebounded after the U.S. and Israel launched an attack on Iran, causing oil prices to spike; WTI crude prices, while off their highs, indicate a defensive market stance.
- CrowdStrike Upgrade: Piper Sandler upgraded CrowdStrike from hold to buy with a $520 price target, arguing that the nearly 19% year-to-date pullback is excessive, and sees AI as an opportunity rather than a threat, boosting market confidence.
- Nvidia Strategic Investments: Nvidia shares rose over 3% after being named a top pick by Morgan Stanley, with analysts noting that despite stagnant stock performance in the last two quarters, business has strengthened; the company announced $2 billion investments in both Coherent and Lumentum, highlighting its strategic focus in optics technology.
- Investor Recommendations: Jim Cramer advised investors without Nvidia positions to buy the stock, asserting that its current depressed price won't last long, even as Monday's gains still left shares lower year-to-date.
See More
Jim Cramer's Investment Advice Amid Middle East Tensions
- Selective Investment Strategy: Jim Cramer advises investors to be selective following the U.S.-Israeli conflict with Iran, noting that while stocks initially sold off, there is no need for a full portfolio overhaul, particularly as the long-term narrative around artificial intelligence remains intact.
- Healthcare Sector Opportunities: Cramer recommends investing in the healthcare sector, asserting it will remain insulated from economic fallout, and initiated a position in Cardinal Health on Monday morning, which plays a crucial role in healthcare distribution and is pursuing growth through acquisitions.
- Reducing Oil Exposure: Cramer highlights that the market reaction creates opportunities to lighten oil positions, suggesting a 50% reduction in holdings due to inflated valuations from rising oil prices, drawing on historical patterns where such stocks tend to decline after initial spikes.
- Cautious on Consumer Staples: While Procter & Gamble is typically viewed as a classic defensive stock, Cramer expresses caution, indicating that rising oil prices could squeeze consumer spending, potentially impacting the performance of such stocks.
See More
Investment Analysis of Cardinal Health
- New Investment Move: Shortly after the opening bell, Jim Cramer's Charitable Trust will purchase 170 shares of Cardinal Health at approximately $229, resulting in a 1% ownership stake, reflecting confidence in the company's prospects.
- Market Reaction: Stocks are expected to open sharply lower on Monday due to weekend strikes in Iran, with crude oil prices climbing above $70, heightening concerns about geopolitical risks and inflation, which complicates the market landscape.
- Long-Term Growth Potential: Cardinal Health plays a crucial role in the U.S. healthcare sector, generating 99% of its revenue domestically, and the ongoing increase in the aging population in the U.S. is expected to provide significant long-term growth tailwinds over the next three decades.
- Profitability Enhancement: Despite market volatility, Cardinal Health's stock has risen over 70% in the past 12 months and approximately 10% year-to-date, trading at a price-to-earnings ratio of 21 times, indicating strong potential for sustained double-digit earnings growth.
See More
Cardinal Health Added to Watchlist
- Strong Industry Position: Cardinal Health serves as a backbone of the U.S. healthcare industry, supplying and distributing medicines and medical products to hospitals, retail pharmacies, and clinics, thereby ensuring its core role in the healthcare supply chain.
- Demographic Tailwind: With the continuous increase in the U.S. population aged 65 and over, Cardinal Health is expected to benefit from this long-term trend, as over 50% of this age group takes four or more medications, driving business growth.
- Market Reaction: Although shares sold off sharply on February 12 due to a logistics company announcing a new tool, the market quickly recognized the overreaction, and the stock rebounded swiftly, demonstrating its economic resilience.
- Attractive Valuation: Despite Cardinal Health's stock gaining about 10% over the past 12 months, it trades at just 21 times 2026 earnings estimates, which remains attractive relative to its historical levels, reflecting its potential for sustained double-digit earnings per share growth.
See More
Biosimilars Drive Cost Savings and Provider Confidence in Healthcare
- Significant Cost Savings: Since 2015, biosimilars have generated over $56 billion in savings for the U.S. healthcare system, not only reducing treatment costs but also enhancing access to care and increasing the overall value of the healthcare system.
- Enhanced Clinical Confidence: A survey of 101 physician practices revealed that nearly 99% of providers feel comfortable explaining biosimilars to patients, demonstrating strong clinical confidence that supports the adoption of these therapies in clinical settings.
- Oncology Market Share Growth: Biosimilars in oncology achieve an average market share of 81% within five years of launch, indicating their critical role and potential in cancer treatment, with expectations for more new approvals in the near future.
- Stable Reimbursement Mechanisms: With 68% of practices rating consistent reimbursement as
See More
Beck Bode Acquires New Stake in Churchill Downs
- New Investment Position: On February 6, 2026, Beck Bode, LLC established a new position in Churchill Downs by acquiring 154,871 shares valued at $17.62 million, indicating confidence in the company's future growth potential.
- Asset Allocation Significance: This acquisition represents 2.93% of Beck Bode's $601.19 million in reportable U.S. equity assets, highlighting the importance of Churchill Downs within its diversified investment portfolio.
- Market Performance Insight: As of February 6, 2026, Churchill Downs shares were priced at $93.55, reflecting a 23.8% decline over the past year, significantly underperforming the S&P 500 by 37.76 percentage points, raising concerns about its future profitability.
- Revenue Diversification Strategy: Churchill Downs leverages its iconic racing assets and technology across live racing, online wagering, and casino operations, aiming for long-term cash flow growth despite potential short-term earnings pressure from aggressive investments in new properties and gaming capacity.
See More
